prevention; (13) reviews Center-wide acquisition and assistance operations to ensure adherence to law, policies, procedures, and regulations; (14) coordinates NCCDPHP requirements relating to small purchase procurement, material management, and interagency agreements; (15) in the conduct of these activities, maintains liaison with other CDC Centers/Institute/Offices, HHS, and other Federal agencies.

Dated: September 14, 1998.

Claire V. Broome,

Acting Director.

[FR Doc. 98–25392 Filed 9–22–98; 8:45 am]

BILLING CODE 4160–18–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Submission for OMB Review; Comment Request

Title: Child Care and Development Fund Plan for States and Territories (Supplement).

OMB No.: 0970–0114.

Description: The Child Care and Development Block Grant (CCDBG) Act of 1990 requires the States and Territories to submit a biennial Plan (ACF–118) in order to receive Federal funds. The statutorily required Plan provides the public and ACF with a description of, and assurances about, the States's Child Care Program. In 1996, the Personal Responsibility and Work Opportunity Reconciliation Act (PRWORA) provided additional fiscal resources for child care but required that the funds be spent in accordance with the provisions of the CCDBG Act. This supplement to the existing Plan reflects the changes made by PRWORA, and provides information to determine in State programs are administered in accordance with the applicable statutes and regulations. The Tribal Plan (ACF–118A) is not effected by this notice.

Respondents: State and Tribal Governments.

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
ACF–118	56	1	4	112

Estimated Total Annual Burden Hours: 112.

Additional Information: Copies of the proposed collection may be obtained by writing to the Administration for Children and Families, Office of Information Services, Division of Information Resource Management Services, 370 L'Enfant Promenade, SW, Washington, DC 20447, Attn: ACF Reports Clearance Officer.

OMB Comment: OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, 725 17th Street, NW, Attn: Ms. Wendy Taylor.

Dated: September 17, 1998.

Bob Sargis,

Acting Reports Clearance Officer.

[FR Doc. 98–25385 Filed 9–22–98; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Cardiovascular and Renal Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on October 22, 1998, 9 a.m. to 5:30 p.m., and October 23, 1998, 9 a.m. to 3 p.m.

Location: National Institutes of Health, Clinical Center, Bldg. 10, Jack Masur Auditorium, 9000 Rockville Pike, Bethesda, MD. Parking in the Clinical Center is reserved for Clinical Center patients and their visitors.

Contact Person: Joan C. Standaert, Center for Drug Evaluation and Research (HFD–110), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 419–259–6211, or John M. Treacy (HFD–21), 301–827–7001, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12533. Please call the Information Line for up-to-date information on this meeting.

Agenda: On October 22, 1998, the committee will discuss guidelines for the study of congestive heart failure. On October 23, 1998, the committee will discuss new drug application (NDA) 20–873, Hirulog (bivalirudin, The Medicine's Co.), injection for anticoagulation in patients undergoing percutaneous transluminal angioplasty.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by October 14, 1998. Oral presentations from the public will be scheduled between approximately 9 a.m. and 10 a.m. on October 23, 1998. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before October 14, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: September 16, 1998.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 98–25360 Filed 9–22–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97N–0510]

Agency Information Collection Activities; Announcement of OMB Approval; Current Good Manufacturing Practice Regulations for Medicated Feeds

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled ''Current Good Manufacturing Practice Regulations for Medicated Feeds'' has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (the PRA).

FOR FURTHER INFORMATION CONTACT: Denver Presley, Office of Information Resources Management (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1472.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of July 10, 1998 (63 FR 37396), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under section 3507 of the PRA (44 U.S.C. 3507). An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0152. The approval expires on August 31, 2001.

Dated: September 16, 1998.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 98–25361 Filed 9–22–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97N–0515]

Agency Information Collection Activities; Announcement of OMB Approval; Current Good Manufacturing Practice for Type A Medicated Articles

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled ''Current Good Manufacturing Practice for Type A Medicated Articles'' has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (the PRA).

FOR FURTHER INFORMATION CONTACT: Denver Presley, Office of Information Resources Management (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1472.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of July 21, 1998 (63 FR 39092), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under section 3507 of the PRA (44 U.S.C. 3507). An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0154. The approval expires on August 31, 2001.

Dated: September 16, 1998.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 98–25362 Filed 9–22–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 98D–0727]

Draft ''Guidance for Industry: Interpretation of On-farm Feed Manufacturing and Mixing Operations''; Availability; Request for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a draft guidance entitled ''Interpretation of On-farm Feed Manufacturing and Mixing Operations.'' The draft guidance is intended to clarify the applicability of certain sections of the Animal Proteins Prohibited from Use in Animal Feed regulation to ruminant feeders. The agency is requesting comments on this draft guidance.

DATES: Submit written comments by November 23, 1998.

ADDRESSES: Submit written requests for single copies of this draft guidance to the Communications Staff (HFV–12), Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855. Send one self-addressed adhesive label to assist that office in processing your requests.

Submit written comments on the draft guidance to the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Comments should be identified with the full title of the draft guidance and the docket number found in brackets in the heading of this document. See the **SUPPLEMENTARY INFORMATION** section for information on electronic access to the draft guidance.

FOR FURTHER INFORMATION CONTACT: Gloria J. Dunnavan, Center for Veterinary Medicine (HFV–230), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1726, E-mail: gdunnava@bangate.fda.gov.

SUPPLEMENTARY INFORMATION:

I. Background

Section 589.2000 *Animal proteins prohibited from use in animal feed* (21 CFR 589.2000) defines ''feed manufacturer'' to include ''on-farm feed manufacturing and mixing operation.'' This draft guidance makes it clear that an operation that mixes, but does not manufacture feed onfarm is not considered a feed manufacturer by FDA. Rather such mixing operations are ruminant feeders. While all ruminant feeders are subject to the regulation, the regulation imposes significantly different requirements on ruminant feeders that are also ''feed manufacturers.'' For this reason, FDA finds it necessary to clarify the phrase ''on-farm feed manufacturing and mixing operations.''

FDA believes that a ruminant producer who mixes total mixed rations (TMR's), a complete mix of the cow's daily diet, for the animals under the producer's control is not